Predicting the Risk of Symptomatic Intracerebral Hemorrhage in Ischemic Stroke Treated With Intravenous Alteplase Safe Implementation of Treatments in Stroke (SITS) Symptomatic Intracerebral Hemorrhage Risk Score

被引:326
作者
Mazya, Michael [1 ]
Egido, Jose A. [2 ]
Ford, Gary A. [3 ]
Lees, Kennedy R. [4 ,5 ]
Mikulik, Robert [6 ]
Toni, Danilo [7 ]
Wahlgren, Nils [1 ]
Ahmed, Niaz [1 ]
机构
[1] Karolinska Univ Hosp, Dept Neurol, Stockholm, Sweden
[2] Univ Complutense Madrid, Hosp Clin San Carlos, Stroke Unit, E-28040 Madrid, Spain
[3] Newcastle Univ, Inst Ageing & Hlth, Stroke Res Grp, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[4] Univ Glasgow, Inst Cardiovasc & Med Sci, Acute Stroke Unit, Glasgow, Lanark, Scotland
[5] Univ Glasgow, Cerebrovasc Clin, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland
[6] St Annes Hosp, Dept Neurol, Int Clin Res Ctr, Brno, Czech Republic
[7] Univ Roma La Sapienza, Dept Neurol & Psychiat, Rome, Italy
关键词
cerebral infarct; database; intracerebral hemorrhage; prognosis; stroke management; thrombolysis; TISSUE-PLASMINOGEN ACTIVATOR; COOPERATIVE ACUTE STROKE; THROMBOLYTIC THERAPY; DOUBLE-BLIND; TRANSFORMATION; TRIAL;
D O I
10.1161/STROKEAHA.111.644815
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-Symptomatic intracerebral hemorrhage (SICH) is a serious complication in patients with acute ischemic stroke treated with intravenous thrombolysis. We aimed to develop a clinical score that can easily be applied to predict the risk of SICH. Methods-We analyzed data from 31 627 patients treated with intravenous alteplase enrolled in the Safe Implementation of Treatments in Stroke (SITS) International Stroke Thrombolysis Register. The outcome measure was SICH per the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST) definition: a Type 2 parenchymal hemorrhage with deterioration in National Institutes of Health Stroke Scale score of >= 4 points or death. Univariate risk factors associated with the outcome were entered into a logistic regression model after stratification of continuous variables. Adjusted ORs for the independent risk factors were converted into points, which were summated to produce a risk score. Results-We identified 9 independent risk factors for SICH: baseline National Institutes of Health Stroke Scale, serum glucose, systolic blood pressure, age, body weight, stroke onset to treatment time, aspirin or combined aspirin and clopidogrel, and history of hypertension. The overall rate of SICH was 1.8%. The risk score ranged from 0 to 12 points and showed a >70-fold graded increase in the rate of SICH for patients with a score >= 10 points (14.3%) compared with a score of 0 point (0.2%). The prognostic discriminating capability by C statistic was 0.70. Conclusions-The SITS SICH risk score predicts large cerebral parenchymal hemorrhages associated with severe clinical deterioration. The score could aid clinicians to identify patients at high as well as low risk of SICH after intravenous alteplase. (Stroke. 2012; 43: 1524-1531.)
引用
收藏
页码:1524 / 1531
页数:8
相关论文
共 33 条
  • [1] Association of Admission Blood Glucose and Outcome in Patients Treated With Intravenous Thrombolysis
    Ahmed, Niaz
    Davalos, Antoni
    Eriksson, Niclas
    Ford, Gary A.
    Glahn, Joerg
    Hennerici, Michael
    Mikulik, Robert
    Kaste, Markku
    Lees, Kennedy R.
    Lindsberg, Perttu J.
    Toni, Danilo
    [J]. ARCHIVES OF NEUROLOGY, 2010, 67 (09) : 1123 - 1130
  • [2] Relationship of Blood Pressure, Antihypertensive Therapy, and Outcome in Ischemic Stroke Treated With Intravenous Thrombolysis Retrospective Analysis From Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR)
    Ahmed, Niaz
    Wahlgren, Nils
    Brainin, Michael
    Castillo, Jose
    Ford, Gary A.
    Kaste, Markku
    Lees, Kennedy R.
    Toni, Danilo
    [J]. STROKE, 2009, 40 (07) : 2442 - 2449
  • [3] Prognosis and prognostic research: validating a prognostic model
    Altman, Douglas G.
    Vergouwe, Yvonne
    Royston, Patrick
    Moons, Karel G. M.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2009, 338 : 1432 - 1435
  • [4] [Anonymous], 1995, NEW ENGL J MED, V333, P1581, DOI [10.1056/NEJM199512143332401, DOI 10.1056/NEJM199512143332401]
  • [5] Hemorrhagic transformation of ischemic brain tissue -: Asymptomatic or symptomatic?
    Berger, C
    Fiorelli, M
    Steiner, T
    Schäbitz, WR
    Bozzao, L
    Bluhmki, E
    Hacke, W
    von Kummer, R
    [J]. STROKE, 2001, 32 (06) : 1330 - 1335
  • [6] Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke
    Brown, DL
    Barsan, WG
    Lisabeth, LD
    Gallery, ME
    Morgenstern, LB
    [J]. ANNALS OF EMERGENCY MEDICINE, 2005, 46 (01) : 56 - 60
  • [7] Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset - The ATLANTIS study: A randomized controlled trial
    Clark, WM
    Wissman, S
    Albers, GW
    Jhamandas, JH
    Madden, KP
    Hamilton, S
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21): : 2019 - 2026
  • [8] The rtPA (Alteplase) 0-to 6-hour acute stroke trial, part A (A0276g) - Results of a double-blind, placebo-controlled, multicenter study
    Clark, WM
    Albers, GW
    Madden, KP
    Hamilton, S
    [J]. STROKE, 2000, 31 (04) : 811 - 816
  • [9] Validation assessment of risk scores to predict postthrombolysis intracerebral haemorrhage
    Cucchiara, Brett
    Kasner, Scott
    Tanne, David
    Levine, Steven
    Demchuk, Andrew
    Messe, Steve
    Sansing, Lauren
    Lees, Kennedy
    Lyden, Patrick
    [J]. INTERNATIONAL JOURNAL OF STROKE, 2011, 6 (02) : 109 - 111
  • [10] Cucchiara Brett, 2008, J Stroke Cerebrovasc Dis, V17, P331, DOI 10.1016/j.jstrokecerebrovasdis.2008.03.012